One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Deep Brain Stimulation Devices Market

[ 英語タイトル ] Deep Brain Stimulation Devices Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0083113
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories (St. Jude Medical)
- Beijing PINS Medical Co. Ltd
- Boston Scientific Corporation
- Fisher Wallace
- Functional Neuromodulation Ltd
- Medtronic PLC
- NeuroPace Inc.
- Renishaw PLC

[Report Description]

The deep brain stimulation devices market is expected to register a CAGR of nearly 12.5% during the forecast period. The major factors driving the growth of the market include the rapidly aging population, which is leading to risk and high prevalence of neurological disorders, growing demand for the devices, due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

- Deep brain stimulation (DBS) is a widely used treatment for advanced Parkinson's disease (PD), essential tremor, and dystonia. However, over the last three decades, in addition to the extension of its clinical applications, there has been tremendous growth in the DBS technology.
- According to the World Ageing 2019 report, estimates that there were about 703 million population aged 65 years or over in the world in 2019. This number is projected to double to 1.5 billion in 2050. Moreover, by 2050, 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019. As number of elderly population are projected to increase and this population are more prone to neurological disorders which ultimately drives the market in near future.
- Currently, there are multiple DBS systems that have been approved by the European and US regulatory agencies. The US Food and Drug Administration (FDA) approved Boston Scientific Corporation’s Vercise Deep Brain Stimulation (DBS) System. This system is used to treat the symptoms of Parkinson's disease (PD). Additionally, researchers are enhancing their existing DBS systems, while developing the next-generation devices.
- The researchers are using DBS to target different areas of the brain and studying the treatment in different populations suffering from Parkinson’s disease. Some changes in the new systems have shown improvement in clinical outcomes. Nevertheless, these new developments in the DBS technology are encouraging a large patient community and healthcare providers.
- Hence, all such advancements in the DBS technology have to lead to the growth of the deep brain stimulation devices market.

Key Market Trends

Parkinson’s Disease Segment is Expected to Hold a Major Market Share in the Deep Brain Stimulation Devices Market

The major factor driving the growth of the segment is the rising global prevalence of Parkinson’s disease. According to Parkinson’s Foundation 2018, approximately 1.2 million people in the United States are estimated to suffer from Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. Similarly, as per the estimates of the NHS UK, Parkinson's disease is found affecting around 1 in 500 people, which means that an estimated 127,000 people in the United Kingdom are suffering from the condition. In addition, there are thousands of patients who go undetected. DBS is the most commonly performed surgical treatment for Parkinson's disease. It is usually done in people, who have been suffering from Parkinson's disease for at least four years and have benefits from medications but have motor complications. Additionally, there is a rising technological advancement in the field of DBS, which is propelling the overall growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

According to the Parkinson’s Foundation Prevalence Project, 930,000 people are estimated to suffer from Parkinson’s disease in the United States, by 2020. The combined direct and indirect costs of Parkinson’s in the United States, including treatment, disability, and similar costs, along with the lost income, owing to the patients’ inability to work, are estimated to be valued at USD 25 billion per year in the United States alone. Hence, the growing burden of Parkinson’s disease on the healthcare system, coupled with uncertain economic conditions in the United States, has forced the original equipment manufacturers (OEMs) to develop cost-effective devices for the treatment of neurological movement disorders.

The US Food and Drug Administration (FDA) approved a deep brain stimulation (DBS) device, namely Brio System, in 2015, for the treatment of Parkinson’s disease and essential tremor. The Brio System’s approval has been good news for the patient community, as it may stimulate more rapid development of the DBS technology.

Additionally, Boston Scientific Corporation received approval from the US Food and Drug Administration (FDA) in December 2017, for its Vercise Deep Brain Stimulation (DBS) System. Hence, all such product approvals and growing incidences of the Parkinson’s disease have helped in driving the growth of the deep brain stimulation devices market.

Competitive Landscape

The deep brain stimulation devices market is consolidated, owing to the presence of a few major market players. Some of the market players are Abbott Laboratories (St. Jude Medical), Beijing PINS Medical Co. Ltd, Boston Scientific Corporation, Fisher Wallace, Functional Neuromodulation Ltd, Medtronic PLC, NeuroPace Inc., and Renishaw PLC.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapidly Aging Population, Leading to Risk and High Prevalence of Neurological Disorders
4.2.2 Growing Demand for the Devices, Due to Rising Popularity of Minimally Invasive Procedures
4.2.3 Availability of Technologically Advanced Deep Brain Stimulation Devices
4.3 Market Restraints
4.3.1 Risks Associated with Deep Brain Stimulation Procedures
4.3.2 Implementation of Government Policies Negatively Affecting the Market
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Single-channel Deep Brain Stimulator
5.1.2 Dual-channel Deep Brain Stimulator
5.2 By Application
5.2.1 Parkinson's Disease
5.2.2 Essential Tremor
5.2.3 Obsessive Compulsive Disorder
5.2.4 Epilepsy
5.2.5 Dystonia
5.2.6 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Neurological Clinics
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories (St. Jude Medical)
6.1.2 Beijing PINS Medical Co. Ltd
6.1.3 Boston Scientific Corporation
6.1.4 Fisher Wallace
6.1.5 Functional Neuromodulation Ltd
6.1.6 Medtronic PLC
6.1.7 NeuroPace Inc.
6.1.8 Renishaw PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+